Related Experiment Video

Updated: Feb 23, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K

In silico and preclinical drug screening identifies dasatinib as a targeted therapy for T-ALL

S Laukkanen1, T Grönroos1, P Pölönen2

  • 1Tampere Center for Child Health Research, University of Tampere, and Tampere University Hospital, Tampere, Finland.

Blood Cancer Journal
|September 9, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Experiment Videos

Last Updated: Feb 23, 2026

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.8K
A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K

Articles linked to this work by shared authors, journal, and citation graph.

ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.

Annals of oncology : official journal of the European Society for Medical Oncology·2023

Merging and imputation of flow cytometry data: A critical assessment.

Cytometry. Part A : the journal of the International Society for Analytical Cytology·2023

Ex vivo cultures and drug testing of primary acute myeloid leukemia samples: Current techniques and implications for experimental design and outcome.

Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy·2020

Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Leukemia·2020

Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS.

Leukemia·2020

Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.

BMC cancer·2019

Association between diabetic control and progression of monoclonal gammopathy of undetermined significance to multiple myeloma.

Blood cancer journal·2026

Selinexor for myelofibrosis or a drug in search of a disease?

Blood cancer journal·2026

Combination of daratumumab, ixazomib, and lenalidomide with or without dexamethasone for initial therapy of newly diagnosed myeloma.

Blood cancer journal·2026

Detailed immunophenotypic and genetic characterization of bone marrow clonal plasma cells and B-cells in early-stage monoclonal gammopathies.

Blood cancer journal·2026

Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms.

Blood cancer journal·2026

Study of post-translational modifications of p53 in multiple myeloma.

Blood cancer journal·2026

Targeting CKIP-1 for Disease Therapy: Cellular Functions, Molecular Networks, and Clinical Potential.

Cell proliferation·2026

YTHDC1 Orchestrates Glucose and Glutamate Rewiring to Overcome Lethal Metabolic Stress in Triple-Negative Breast Cancer.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Natural Product Toosendanin Suppresses the Malignant Development of Skin Melanoma by Targeting BNC2 for Degradation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

An Immune-Activated Co-culture Model of Patient-Derived Gastric Cancer Organoids and Peripheral Blood Mononuclear Cells for Personalized Chemotherapy Screening.

Acta biomaterialia·2026

Cardio-renal protection of MRAs in kidney-transplanted diabetic patients.

Pharmacological research·2026

Substrate-Derived Peptides for Selective Covalent Inhibition of Protein Tyrosine Kinases.

ACS chemical biology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us